Skip to main content
Premium Trial:

Request an Annual Quote

Decode Genetics Gets Nasdaq Deficiency Notice

NEW YORK (GenomeWeb News) – Decode Genetics said after the close of the market Thursday that it has received a notice from the Nasdaq Stock Market informing the firm that its is not in compliance with certain rule of the market.

Specifically, Nasdaq told the firm that it is not in compliance with the minimum bid price rule, because the closing bid price for its shares has been below $1 per share for 30 consecutive business days.

Decode has until March 15, 2010, to regain compliance with the rule, the company said. It can regain compliance by having its stock close at $1 per share or more for at least 10 consecutive business days any time before March 15.

Last spring, Nasdaq stayed delisting of Decode's stock after it had been under threat of delisting for several months.

Decode's shares closed up 3 percent at $.53.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.